Glucagon-Like Peptide-1 and Blood Pressure in Young and Healthy Adults from the General Population

Abstract

All study participants included in the current analysis are participants of the prospective genetic and phenotypic determinants of BP and other cardiovascular risk factors (GAPP) study. Detailed information Abstract-Hypertension and diabetes mellitus are highly correlated, but the underlying mechanisms are only partly understood.Therefore, the aim of our study was to investigate the relationships between plasma levels of glucagon-like peptide-1, a key factor in the regulation of glucose homeostasis, and various blood pressure indices. Healthy adults aged 25 to 41 years were enrolled in a population-based study. Established cardiovascular disease, diabetes mellitus, or a body mass index >35 kg/m 2 were exclusion criteria. Fasting plasma glucagon-like peptide-1 levels as determined with a novel high-sensitive assay and ambulatory blood pressure data were available in 1479 participants not using antihypertensive treatment. Median age of our population was 38 years. Mean systolic and diastolic blood pressure across increasing glucagon-like peptide-1 quartiles were 120.6, 122.8, 123.2, and 124.9 mm Hg and 77.1, 78.7, 78.9, and 79.9 mm Hg, respectively. We found a linear relationship of glucagon-like peptide-1 with 24-hour ambulatory blood pressure after multivariable adjustment (β per 1 log-unit increase 2.01; 95% confidence interval, 1.02-3.00; P<0.0001 for systolic and 1.22; 0.47-1.97; P=0.002 for diastolic blood pressure). In separate analyses, glucagon-like peptide-1 was significantly related to both awake (β per 1 logunit increase 2.05; 1.02-3.09; P=0.0001 for systolic and 1.15; 0.35-1.96; P=0.005 for diastolic blood pressure) and asleep blood pressure (β per 1 log-unit increase 1.34; 0.26-2.42; P=0.01 for systolic and 1.05; 0.26-1.84; P=0.009 for diastolic blood pressure). In conclusion, plasma levels of glucagon-like peptide-1 are significantly associated with both systolic and diastolic blood pressure levels. (Hypertension. 2015;65:306-312.

Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials

“…Our meta-analysis showed that SBP was reduced by approximately 5 mmHg, which may be a cardioprotective benefit. A study based on healthy adults found that plasma levels of fasting GLP-1 are significantly and positively related to the blood pressure indices assessed [60]. The increase in GLP-1 levels could be a compensatory response to individual BP elevations.…”

Different mechanisms involved in liraglutide and glucagon‐like peptide‐1 vasodilatation in rat mesenteric small arteries

“…Nevertheless, we found an effect of GLP‐1 on hyperglycaemia‐induced impairment of endothelium‐dependent relaxation, but as we were not able to show a similar effect of liraglutide, it is uncertain if this is the major mechanism resulting in the lowering of BP in diabetic patients treated with GLP‐1 analogues. Furthermore, it is noteworthy that GLP‐1 plasma levels have been found to be associated with BP in normoglycaemic young healthy adults as well (Krisai et al ., ), demonstrating that there may be other GLP‐1 effects of importance that affect BP.…”

A Novel GLP1 Receptor Interacting Protein ATP6ap2 Regulates Insulin Secretion in Pancreatic Beta Cells

“…In the heart, the cardiac effects of GLP1 analogs have led to the amelioration of myocardial ischemia and to the restriction of infarct size (9), and GLP1 infusion could improve heart function (10). GLP1 in plasma was associated with blood pressure levels in a human population study (11). Further, GLP1 or its analogs were shown to lower blood pressure in rodents and human subjects (12)(13)(14).…”